Dynavax Technologies Corporation has reported that its experimental shingles vaccine demonstrates an immune response comparable to that of GSK’s well-established vaccine, Shingrix. This finding...
BioNTech has reached a settlement in a three-year patent dispute involving mRNA technology with GlaxoSmithKline (GSK) and CureVac. As part of this agreement, both...